Today: 19 May 2026
Browse Category

NYSE:ABBV 10 January 2026 - 26 January 2026

AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie stock price edges up: what investors watch ahead of Feb. 4 earnings

AbbVie shares rose 0.4% to $220.10 Monday, moving between $217.15 and $221.48 as investors awaited its Feb. 4 earnings report. Health-care stocks held firm, with the sector ETF up 0.4% and Johnson & Johnson and Pfizer also gaining. AbbVie’s upcoming results will highlight its immunology drugs as it faces pressure from declining Humira sales and recent policy deals. Traders are watching Wednesday’s Fed decision before the earnings release.
26 January 2026
···
AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie shares rose 0.5% to $219.26 Friday, shrugging off India’s rejection of its patent application for the cancer drug venetoclax. The Indian patent office cited lack of novelty and opposition from seven parties. AbbVie will report Q4 and full-year earnings on Feb. 4. Investors remain focused on patent risks and upcoming guidance as the company adjusts after Humira’s decline.
25 January 2026
···
AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie stock rises after-hours as Bernstein sticks with $225 target ahead of Feb. 4 earnings

AbbVie shares closed up 0.99% at $216.15 Wednesday, trading near typical volume ahead of its Feb. 4 earnings report. Bernstein’s Courtney Breen maintained a Market Perform rating and $225 target. Investors are watching for 2026 guidance and updates on AbbVie’s new drug performance. Details of a recent pricing deal with the Trump administration remain undisclosed.
22 January 2026
·
AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie shares fell 1.1% to $214.35 Friday after partner Genmab said their blood cancer drug epcoritamab failed to meet the main survival goal in a Phase 3 trial. Genmab’s U.S. shares dropped over 7%. AbbVie reported a benefit for progression-free survival but not overall survival. Investors await AbbVie’s earnings report on Feb. 4.
18 January 2026
····
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie shares fell 1.1% to $214.35 Friday after its lymphoma drug epcoritamab met a key trial goal but failed to show a statistically significant overall survival benefit. The company said it will consult regulators on next steps. AbbVie also outlined plans to expand into obesity drugs and will report earnings Feb. 4. U.S. markets close Monday for Martin Luther King Jr. Day.
16 January 2026
···
AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie shares rose about 0.5% to $221.89 in after-hours trading Wednesday after executives outlined plans to expand into obesity treatments. The company is betting on GUBamy, a drug licensed from Denmark’s Gubra, and highlighted its focus on amylin-based therapies. Investors are watching for pricing pressure from Washington ahead of AbbVie’s Feb. 4 earnings report.
15 January 2026
··
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson shares rose 1.9% to $217.80 by late morning Wednesday, outperforming a 1% drop in the S&P 500. Delaware’s Supreme Court threw out part of a ruling tied to Auris Health merger payments, possibly cutting damages by hundreds of millions. Legal battles over talc litigation continue. J&J’s Q4 earnings call is scheduled for Jan. 21.
14 January 2026
······
AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie shares fell 0.1% to $219.83 Tuesday after announcing a three-year U.S. pricing deal tied to tariff exemptions. The company also signed a $650 million licensing agreement with China’s RemeGen for rights to an experimental cancer drug and bought a manufacturing site in Arizona. Management is set to speak at the J.P. Morgan Healthcare Conference on Jan. 14.
13 January 2026
··
AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie shares fell 0.6% to $218.81 after announcing a $650 million licensing deal with China’s RemeGen for the experimental cancer drug RC148. RemeGen could receive up to $4.95 billion in milestones and royalties. AbbVie also agreed to buy a device manufacturing plant in Tempe, Arizona, from West Pharmaceutical Services. The S&P health-care sector declined while the broader market rose.
12 January 2026
···
Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

U.S. healthcare stocks fell this week, with the XLV ETF down 0.5% to $157.31, even as the S&P 500 hit a record high. Two biotech firms, Eikon Therapeutics and Veradermics, filed for IPOs. Healthcare M&A value rose 56% in 2025 to $403 billion, despite fewer deals. Insmed reported preliminary 2025 ARIKAYCE sales of $433.8 million and set a 2026 revenue target of $450–470 million.
10 January 2026
···
1 2 3 4 5

Stock Market Today

  • Chart Patterns Signal Potential Rise in Treasury Yields Amid New Interest Rate Era
    May 19, 2026, 7:15 AM EDT. A "pennant" chart pattern suggests U.S. Treasury yields could climb significantly, indicating a possible shift to a higher interest rate environment. Treasury yields, which reflect government borrowing costs and influence borrowing rates economy-wide, have remained volatile amid economic uncertainty. The pattern warns investors to brace for rising rates, which could pressure bonds and stocks. However, analysts note an alternative scenario where yields might not surge as much, adding complexity to market outlooks. This development underscores the challenges in forecasting fixed income markets and the potential for renewed volatility.

Latest articles

Meiwu Technology Stock Jumps 88% Premarket After Monday Rout — What’s Moving WNW Now

Meiwu Technology Stock Jumps 88% Premarket After Monday Rout — What’s Moving WNW Now

19 May 2026
Meiwu Technology shares surged 87.99% to $4.531 in premarket trading Tuesday after a 22.76% drop Monday, which left the stock at $2.410. The company recently raised $15.65 million in a private share sale at $0.626 per share, with proceeds earmarked for an AI-driven skincare platform and related projects. Meiwu reported 2025 revenue of $7.08 million and a net loss of $18.59 million.
Standard Chartered’s Push Into AI May Cut 7,000 Jobs as Bank Looks for 18% Returns

Standard Chartered’s Push Into AI May Cut 7,000 Jobs as Bank Looks for 18% Returns

19 May 2026
Standard Chartered will cut over 7,000 jobs by 2030 and aims for an 18% return on tangible equity, focusing on AI and automation to boost efficiency. The bank reported record Q1 operating income of $5.9 billion and profit before tax of $2.5 billion. Job cuts will mainly affect corporate and support roles in hubs like Bengaluru, Tianjin, and Warsaw. The bank seeks to attract $200 billion in new wealth by 2028.

Popular

Intel Shares Edge Up as AI Chip Trade Runs Into Hurdles

Intel Shares Edge Up as AI Chip Trade Runs Into Hurdles

18 May 2026
Intel shares rose 0.3% to $109.10 in early New York trading Monday after last week’s selloff, as analysts raised price targets and President Trump commented on the U.S. government’s 10% stake, now valued above $50 billion. First-quarter revenue climbed 7% to $13.6 billion, with Data Center and AI sales up 22%. The iShares Semiconductor ETF fell 0.9%. Intel’s server CPU market share dropped to 54.9% in Q1, according to UBS.
Go toTop